SG Americas Securities
SNDX icon

SG Americas Securities’s Syndax Pharmaceuticals SNDX Stock Holding History

SG Americas Securities’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683K Sell
31,254
-7,294
-19% -$152K ﹤0.01% 2138
2026
Q1 		$900K Sell
38,548
-90,679
-70% -$1.97M ﹤0.01% 1828
2025
Q4 		$2.71M Buy
129,227
+83,801
+184% +$1.46M ﹤0.01% 1361
2025
Q3 		$699K Buy
+45,426
New +$595K ﹤0.01% 1807
2024
Q3 		– Sell
-31,051
Closed -$637K – 3585
2024
Q2 		$637K Buy
+31,051
New +$650K ﹤0.01% 1546
2024
Q1 		– Sell
-29,169
Closed -$630K – 3406
2023
Q4 		$630K Buy
29,169
+19,328
+196% +$297K 0.01% 1318
2023
Q3 		$143K Buy
+9,841
New +$186K ﹤0.01% 2538
2023
Q2 		– Sell
-90,137
Closed -$1.9M – 3092
2023
Q1 		$1.9M Buy
90,137
+83,238
+1,207% +$2.07M 0.02% 693
2022
Q4 		$176K Sell
6,899
-15,967
-70% -$372K ﹤0.01% 2293
2022
Q3 		$549K Sell
22,866
-6,441
-22% -$145K 0.01% 1473
2022
Q2 		$564K Buy
29,307
+4,808
+20% +$80.1K 0.01% 1861
2022
Q1 		$426K Buy
24,499
+18,975
+344% +$319K ﹤0.01% 1988
2021
Q4 		$121K Sell
5,524
-22,726
-80% -$420K ﹤0.01% 2963
2021
Q3 		$540K Buy
+28,250
New +$471K ﹤0.01% 2426
2021
Q2 		– Sell
-7,832
Closed -$175K – 3205
2021
Q1 		$175K Buy
7,832
+3,023
+63% +$68.3K ﹤0.01% 2761
2020
Q4 		$107K Buy
+4,809
New +$99.7K ﹤0.01% 3003
2020
Q3 		– Sell
-14,812
Closed -$220K – 3384
2020
Q2 		$220K Buy
+14,812
New +$226K ﹤0.01% 2783
2019
Q2 		– Sell
-10,558
Closed -$55K – 3384
2019
Q1 		$55K Buy
+10,558
New +$60.2K ﹤0.01% 3178

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

SG Americas Securities's SNDX Position: Q2 2026 in Review

SG Americas Securities reduced its Syndax Pharmaceuticals (SNDX) stake by 19% in Q2 2026, selling an estimated $152K and leaving 31,254 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

SG Americas Securities first reported a position in SNDX in Q1 2019 and has held it in 18 quarters since. The position peaked at $2.71M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • SG Americas Securities held 31,254 shares of Syndax Pharmaceuticals worth $683K as of Q2 2026.
  • SG Americas Securities sold 7,294 Syndax Pharmaceuticals shares in Q2 2026, an estimated $152K.
  • Syndax Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2138 holding.
  • SG Americas Securities first reported a position in Syndax Pharmaceuticals in Q1 2019 and has held it in 18 quarters since.
  • SG Americas Securities's Syndax Pharmaceuticals position peaked at $2.71M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.